Brain and Development 2004-01-01

Unusual side-effects due to clobazam: a case report with genetic study of CYP2C19.

Antonia Parmeggiani, Annio Posar, Simonetta Sangiorgi, Paola Giovanardi-Rossi

Index: Brain Dev. 26(1) , 63-6, (2004)

Full Text: HTML

Abstract

We describe the case of a 10-year-old girl with two epileptic seizures and subcontinuous spike-waves during sleep, who presented unusual side-effects related to clobazam (CLB) monotherapy. High plasma levels of N-desmethyl-clobazam (N-CLB), the major metabolite of CLB were detected. The patient and her parents underwent molecular analysis of the CYP2C19 gene, which may be implicated in the metabolism of this drug. Our patient presents one copy of the most common mutation (CYP2C19*2) affecting the activity of the isoenzyme and probably another rare or private mutation. CLB and N-CLB plasma level dosages and molecular analysis may be useful when a poor metabolic condition is suspected.


Related Compounds

Related Articles:

Blood concentrations of clobazam and norclobazam in a lethal case involving clobazam, meprobamate and clorazepate.

2010-11-01

[Leg. Med. (Tokyo.) 12(6) , 300-4, (2010)]

Simultaneous determination of clobazam and its major metabolite in human plasma by a rapid HPLC method.

2005-09-05

[J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 823(2) , 167-71, (2005)]

A major influence of CYP2C19 genotype on the steady-state concentration of N-desmethylclobazam.

2004-12-01

[Brain Dev. 26(8) , 530-4, (2004)]

Analysis of clobazam and its active metabolite norclobazam in plasma and serum using HPLC/DAD.

1996-11-01

[Scand. J. Clin. Lab. Invest. 56(7) , 609-14, (1996)]

Eye rolling as a manifestation of clobazam toxicity in a child with epilepsy.

2006-07-01

[Dev. Med. Child Neurol. 48(7) , 612-5, (2006)]

More Articles...